Novo Nordisk’s Wegovy delivered sales that beat Wall Street expectations, widening the company’s early competitive lead in obesity medicines, according to the report. The quarter’s results prompted guidance upgrades and helped Novo strengthen its position amid growing pressure from Eli Lilly’s oral obesity candidates. The company’s next moves will likely hinge on how quickly oral GLP-1 pathway products convert prescribing and whether Novo can sustain momentum through product-cycle transitions, including the pill’s rollout dynamics.